Can oral minoxidil be the game changer in androgenetic alopecia? A comprehensive review and meta-analysis comparing topical and oral minoxidil for treating androgenetic alopecia.

Q3 Medicine
Skin health and disease Pub Date : 2025-04-25 eCollection Date: 2025-04-01 DOI:10.1093/skinhd/vzaf009
Faizan Fazal, Bilal Haider Malik, Haris Mumtaz Malik, Beenish Sabir, Haris Mustafa, Mushood Ahmed, Areesha Abid, Maham Leeza Adil, Umar Shafi, Muhammad Saad
{"title":"Can oral minoxidil be the game changer in androgenetic alopecia? A comprehensive review and meta-analysis comparing topical and oral minoxidil for treating androgenetic alopecia.","authors":"Faizan Fazal, Bilal Haider Malik, Haris Mumtaz Malik, Beenish Sabir, Haris Mustafa, Mushood Ahmed, Areesha Abid, Maham Leeza Adil, Umar Shafi, Muhammad Saad","doi":"10.1093/skinhd/vzaf009","DOIUrl":null,"url":null,"abstract":"<p><p>Androgenetic alopecia (AGA) is a hair disorder seen in both sexes. Its aetiology is multifactorial. Treating AGA has always been a challenge for dermatologists. Only a few drugs such as topical minoxidil and finasteride are U.S. Food and Drug Administration-approved for treating AGA. Thus, looking for new and more effective treatment options for AGA is imperative. This review was conducted to compare the efficacy of oral with topical minoxidil in treating AGA. Only clinical trials that compared oral with topical minoxidil in treating AGA were included in this review. PubMed, Cochrane, Scopus and ClinicalTrials.gov were searched. A total of 2063 studies were retrieved from the databases. Four studies met the inclusion criteria and were included in this systematic review. Outcomes such as hair density, terminal hair density, hair count, global photographic assessment and negative hair pull were studied in this review. The results showed that there was no significant difference between oral and topical minoxidil in terms of improving the hair density of patients with AGA (overall mean difference 0.95, 95% confidence interval -24.98 to 26.87). Two studies showed that the mean difference in terminal hair density was greater in patients treated with oral minoxidil, but there was no significant difference between the two treatments in terms of improving terminal hair density. The efficacy of oral minoxidil is comparable to that of topical minoxidil in terms of improving hair density and terminal hair density in patients with AGA. Oral minoxidil can be used as an adjunct or as a second-line treatment option for AGA.</p>","PeriodicalId":74804,"journal":{"name":"Skin health and disease","volume":"5 2","pages":"95-101"},"PeriodicalIF":0.0000,"publicationDate":"2025-04-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12068484/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Skin health and disease","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1093/skinhd/vzaf009","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/4/1 0:00:00","PubModel":"eCollection","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

Abstract

Androgenetic alopecia (AGA) is a hair disorder seen in both sexes. Its aetiology is multifactorial. Treating AGA has always been a challenge for dermatologists. Only a few drugs such as topical minoxidil and finasteride are U.S. Food and Drug Administration-approved for treating AGA. Thus, looking for new and more effective treatment options for AGA is imperative. This review was conducted to compare the efficacy of oral with topical minoxidil in treating AGA. Only clinical trials that compared oral with topical minoxidil in treating AGA were included in this review. PubMed, Cochrane, Scopus and ClinicalTrials.gov were searched. A total of 2063 studies were retrieved from the databases. Four studies met the inclusion criteria and were included in this systematic review. Outcomes such as hair density, terminal hair density, hair count, global photographic assessment and negative hair pull were studied in this review. The results showed that there was no significant difference between oral and topical minoxidil in terms of improving the hair density of patients with AGA (overall mean difference 0.95, 95% confidence interval -24.98 to 26.87). Two studies showed that the mean difference in terminal hair density was greater in patients treated with oral minoxidil, but there was no significant difference between the two treatments in terms of improving terminal hair density. The efficacy of oral minoxidil is comparable to that of topical minoxidil in terms of improving hair density and terminal hair density in patients with AGA. Oral minoxidil can be used as an adjunct or as a second-line treatment option for AGA.

口服米诺地尔能改变雄激素性脱发吗?比较外用和口服米诺地尔治疗雄激素性脱发的综合综述和荟萃分析。
雄激素性脱发(AGA)是一种男女皆有的头发疾病。其病因是多因素的。治疗AGA对皮肤科医生来说一直是一个挑战。只有少数药物,如局部米诺地尔和非那雄胺,被美国食品和药物管理局批准用于治疗AGA。因此,寻找新的更有效的AGA治疗方案势在必行。本综述旨在比较口服米诺地尔与外用米诺地尔治疗AGA的疗效。只有比较口服米诺地尔与外用米诺地尔治疗AGA的临床试验被纳入本综述。检索了PubMed、Cochrane、Scopus和ClinicalTrials.gov。从数据库中共检索到2063项研究。四项研究符合纳入标准,被纳入本系统综述。本综述研究了发密度、终末发密度、发数、全摄评估和阴性拔毛等结果。结果显示,口服米诺地尔与外用米诺地尔在改善AGA患者毛发密度方面无显著差异(总体平均差值0.95,95%可信区间为-24.98 ~ 26.87)。两项研究表明,口服米诺地尔治疗的患者终末毛密度的平均差异更大,但两种治疗在改善终末毛密度方面无显著差异。在改善AGA患者的发密度和终末发密度方面,口服米诺地尔与外用米诺地尔的疗效相当。口服米诺地尔可作为AGA的辅助治疗或二线治疗选择。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
1.70
自引率
0.00%
发文量
0
审稿时长
10 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信